{"sequenceId":"845361811291","id":"34207098066","language":"English","title":"Zacks: Brokerages Anticipate Amicus Therapeutics, Inc. (FOLD) to Post -$0.33 EPS","content":"Wall Street brokerages expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to post earnings per share (EPS) of ($0.33) for the current fiscal quarter, according to Zacks Investment Research . Three analysts have made estimates for Amicus Therapeutics’ earnings. Amicus Therapeutics reported earnings per share of ($0.34) in the same quarter last year, which would suggest a positive year-over-year growth rate of 2.9%. The firm is expected to issue its next earnings report on Monday, August 6th.    On average, analysts expect that Amicus Therapeutics will report full-year earnings of ($1.27) per share for the current financial year, with EPS estimates ranging from ($1.58) to ($0.99). For the next year, analysts forecast that the company will post earnings of ($0.98) per share, with EPS estimates ranging from ($1.42) to ($0.47). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover Amicus Therapeutics.     Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.08. Amicus Therapeutics had a negative net margin of 563.98% and a negative return on equity of 60.09%. The firm had revenue of $16.70 million for the quarter, compared to the consensus estimate of $16.78 million.    FOLD has been the topic of several recent research reports. Leerink Swann upped their target price on shares of Amicus Therapeutics from $20.00 to $24.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Zacks Investment Research raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 20th. Robert W. Baird set a $20.00 target price on shares of Amicus Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 7th. BidaskClub downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 13th. Finally, ValuEngine raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $19.06.  FOLD traded down $0.39 during trading hours on Friday, hitting $16.51. 1,624,860 shares of the company’s stock were exchanged, compared to its average volume of 2,979,463. Amicus Therapeutics has a 12-month low of $8.04 and a 12-month high of $17.40. The company has a market cap of $3.21 billion, a P/E ratio of -5.65 and a beta of 1.48. The company has a quick ratio of 4.15, a current ratio of 4.21 and a debt-to-equity ratio of 0.32.    In other Amicus Therapeutics news, insider Jay Barth sold 5,000 shares of the stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $15.05, for a total value of $75,250.00. Following the sale, the insider now directly owns 90,409 shares of the company’s stock, valued at approximately $1,360,655.45. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website . Also, Director Margaret G. Mcglynn sold 10,000 shares of the stock in a transaction that occurred on Wednesday, May 16th. The shares were sold at an average price of $16.00, for a total transaction of $160,000.00. Following the completion of the sale, the director now directly owns 25,814 shares in the company, valued at $413,024. The disclosure for this sale can be found here . Over the last three months, insiders sold 128,750 shares of company stock worth $1,921,300. Insiders own 2.90% of the company’s stock.    Several large investors have recently made changes to their positions in FOLD. Palisade Capital Management LLC NJ purchased a new stake in shares of Amicus Therapeutics in the 1st quarter valued at approximately $211,000. Xact Kapitalforvaltning AB purchased a new position in shares of Amicus Therapeutics in the 4th quarter valued at $219,000. Rockefeller Financial Services Inc. purchased a new position in shares of Amicus Therapeutics in the 4th quarter valued at $276,000. Rockefeller Capital Management L.P. purchased a new position in shares of Amicus Therapeutics in the 1st quarter valued at $288,000. Finally, WINTON GROUP Ltd purchased a new position in shares of Amicus Therapeutics in the 1st quarter valued at $383,000.    About Amicus Therapeutics    Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.    Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)    For more information about research offerings from Zacks Investment Research, visit Zacks.com","contentWithMarkup":"Wall Street brokerages expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to post earnings per share (EPS) of ($0.33) for the current fiscal quarter, according to Zacks Investment Research . Three analysts have made estimates for Amicus Therapeutics’ earnings. Amicus Therapeutics reported earnings per share of ($0.34) in the same quarter last year, which would suggest a positive year-over-year growth rate of 2.9%. The firm is expected to issue its next earnings report on Monday, August 6th.    On average, analysts expect that Amicus Therapeutics will report full-year earnings of ($1.27) per share for the current financial year, with EPS estimates ranging from ($1.58) to ($0.99). For the next year, analysts forecast that the company will post earnings of ($0.98) per share, with EPS estimates ranging from ($1.42) to ($0.47). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover Amicus Therapeutics.     Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.08. Amicus Therapeutics had a negative net margin of 563.98% and a negative return on equity of 60.09%. The firm had revenue of $16.70 million for the quarter, compared to the consensus estimate of $16.78 million.    FOLD has been the topic of several recent research reports. Leerink Swann upped their target price on shares of Amicus Therapeutics from $20.00 to $24.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Zacks Investment Research raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 20th. Robert W. Baird set a $20.00 target price on shares of Amicus Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 7th. BidaskClub downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 13th. Finally, ValuEngine raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $19.06.  FOLD traded down $0.39 during trading hours on Friday, hitting $16.51. 1,624,860 shares of the company’s stock were exchanged, compared to its average volume of 2,979,463. Amicus Therapeutics has a 12-month low of $8.04 and a 12-month high of $17.40. The company has a market cap of $3.21 billion, a P/E ratio of -5.65 and a beta of 1.48. The company has a quick ratio of 4.15, a current ratio of 4.21 and a debt-to-equity ratio of 0.32.    In other Amicus Therapeutics news, insider Jay Barth sold 5,000 shares of the stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $15.05, for a total value of $75,250.00. Following the sale, the insider now directly owns 90,409 shares of the company’s stock, valued at approximately $1,360,655.45. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website . Also, Director Margaret G. Mcglynn sold 10,000 shares of the stock in a transaction that occurred on Wednesday, May 16th. The shares were sold at an average price of $16.00, for a total transaction of $160,000.00. Following the completion of the sale, the director now directly owns 25,814 shares in the company, valued at $413,024. The disclosure for this sale can be found here . Over the last three months, insiders sold 128,750 shares of company stock worth $1,921,300. Insiders own 2.90% of the company’s stock.    Several large investors have recently made changes to their positions in FOLD. Palisade Capital Management LLC NJ purchased a new stake in shares of Amicus Therapeutics in the 1st quarter valued at approximately $211,000. Xact Kapitalforvaltning AB purchased a new position in shares of Amicus Therapeutics in the 4th quarter valued at $219,000. Rockefeller Financial Services Inc. purchased a new position in shares of Amicus Therapeutics in the 4th quarter valued at $276,000. Rockefeller Capital Management L.P. purchased a new position in shares of Amicus Therapeutics in the 1st quarter valued at $288,000. Finally, WINTON GROUP Ltd purchased a new position in shares of Amicus Therapeutics in the 1st quarter valued at $383,000.    About Amicus Therapeutics    Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.    Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)    For more information about research offerings from Zacks Investment Research, visit Zacks.com","tags":[],"publishedDate":"2018-06-02T21:20:38Z","harvestDate":"2018-06-02T21:21:13Z","estimatedPublishedDate":"2018-06-02T21:20:38Z","url":"http://ct.moreover.com/?a=34207098066&p=1u0&v=1&x=Nn6PzGWOSLwYQgzMlyPkag","originalUrl":"https://www.americanbankingnews.com/2018/06/02/zacks-brokerages-anticipate-amicus-therapeutics-inc-fold-to-post-0-33-eps.html","outboundUrls":["https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1","http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1","http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&Symbol=FOLD","https://www.marketbeat.com/stocks/NASDAQ/FOLD/","https://www.sec.gov/Archives/edgar/data/1178879/000120919118019413/xslF345X03/doc4.xml","https://www.sec.gov/Archives/edgar/data/1178879/000120919118031546/xslF345X03/doc4.xml","https://www.zacks.com/registration/pfp/?ALERT=zrmodule&ADID=AMERBMN_CONTENT_ZER&skip_rpt_name_check=skip_rpt_name_check&t=FOLD"],"wordCount":"779","dataFormat":"text","duplicateGroupId":"34207098066","media":{"audio":[],"images":[],"video":[],"logo":[]},"publishingPlatform":{},"adultLanguage":"false","topics":[{"name":"Finance latest","group":"Finance"}],"companies":[{"name":"Amicus Therapeutics Inc","symbol":"AM6","exchange":"BER","isin":"US03152W1099","titleCount":1,"contentCount":22,"primary":true},{"name":"Amicus Therapeutics Inc","symbol":"FOLD","exchange":"NAS","isin":"US03152W1099","titleCount":1,"contentCount":22,"primary":true},{"name":"Amicus Therapeutics Inc","symbol":"AM6","exchange":"FRA","isin":"US03152W1099","titleCount":1,"contentCount":22,"primary":true},{"name":"Amicus Therapeutics Inc","symbol":"AM6","exchange":"STU","isin":"US03152W1099","titleCount":1,"contentCount":22,"primary":true}],"author":{"publishingPlatform":{}},"licenses":[{"name":"CLA"}],"source":{"name":"American Banking News","homeUrl":"http://americanbankingnews.com","category":"Trade","editorialRank":"3","industry":"Banking & Finance","location":{"country":"United States","countryCode":"US","region":"Americas","subregion":"Northern America"},"feed":{"id":"246729953","name":"American Banking News","mediaType":"News","tags":[],"language":"Unassigned","dataFormat":"text","rank":{"inboundLinkCount":"49331"},"inWhiteList":"true","autoTopics":[],"editorialTopics":["Professional","Financials","Banking"],"genre":"General"}},"es_id":86989879}